PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$11.92 0.3  2.2%

Last Trade - 2:56pm

Small Cap
Market Cap £241.1m
Enterprise Value £186.7m
Revenue £n/a
Position in Universe 4270th / 7277

PDS Biotechnology Set to Join Russell Microcap® Index

Mon 7th June, 2021 1:00pm
For best results when printing this announcement, please click on link below:

FLORHAM PARK, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies based on the Company’s proprietary Versamune(®)
T-cell activating technology, today announced the Company is set to join the
Russell Microcap(®) Index at the conclusion of the 2021 Russell indexes
annual reconstitution, effective after the US market opens on June 28,
according to a preliminary list of additions posted June 4.

Membership in the Russell Microcap(®) Index, which remains in place for one
year, means automatic inclusion in the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes primarily
by objective, market-capitalization rankings and style attributes.

"Inclusion in the Russell Microcap Index underscores the progress we are
making to increase shareholder value by driving our three (3) Phase 2 clinical
programs forward for our lead HPV-cancer immunotherapy PDS0101, including an
oral presentation of interim data for our National Cancer Institute-led trial
at the American Society of Clinical Oncology annual meeting later today," said
Dr. Frank Bedu-Addo, President and CEO of PDS Biotech. "Inclusion in the Index
significantly benefits our Company and shareholders by elevating our
visibility within the global investment community. We look forward to
continuing to progress the clinical development of PDS0101 while also moving
additional oncology pipeline products into human testing within the next

Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
Approximately $10.6 trillion in assets are benchmarked against Russell’s US
indexes. Russell indexes are part of FTSE Russell, a leading global index

For more information on the Russell Microcap(®) Index and the Russell indexes
reconstitution, go to the “Russell Reconstitution” section on the FTSE
Russell website

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing
pipeline of cancer immunotherapies based on the Company’s proprietary
Versamune(®) T-cell activating technology platform. Our Versamune(®)-based
products overcome the limitations of current immunotherapy by inducing in
vivo, large quantities of high-quality, highly potent polyfunctional tumor
specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed
multiple therapies, based on combinations of Versamune(®) and
disease-specific antigens, designed to train the immune system to better
recognize diseased cells and effectively attack and destroy them. Our
immuno-oncology product candidates are initially being studied in combination
therapy to potentially enhance efficacy without compounding toxicity across a
range of cancer types. The company’s lead investigational cancer
immunotherapy product PDS0101 is currently in Phase 2 clinical studies in
HPV-associated cancers. The company’s pipeline products address various
cancers including breast, colon, lung, prostate and ovarian cancers. To learn
more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset classes in
more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by
institutional and retail investors globally. Approximately $17.9 trillion is
currently benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks have chosen
FTSE Russell indexes to benchmark their investment performance and create
ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and
management: a transparent rules-based methodology is informed by independent
committees of leading market participants. FTSE Russell is focused on applying
the highest industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation and
customer partnerships as it seeks to enhance the breadth, depth and reach of
its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more
information, visit www.ftserussell.com.

Forward Looking Statements

This communication contains forward-looking statements (including within the
meaning of Section 21E of the United States Securities Exchange Act of 1934,
as amended, and Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”) and
other matters. These statements may discuss goals, intentions and expectations
as to future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company’s
management, as well as assumptions made by, and information currently
available to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,”
“forecast,” “guidance”, “outlook” and other similar expressions
among others. Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not guarantees
of future performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various factors,
including, without limitation: the Company’s ability to protect its
intellectual property rights; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and the
Company’s current expectations regarding its plans for future equity
financings; the Company’s dependence on additional financing to fund its
operations and complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may restrict
the Company’s operations or require the Company to relinquish rights to the
Company’s technologies or product candidates; the Company’s limited
operating history in the Company’s current line of business, which makes it
difficult to evaluate the Company’s prospects, the Company’s business plan
or the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to initiate the
planned clinical trials for PDS0101, PDS0203 and other Versamune(®) based
products; the future success of such trials; the successful implementation of
the Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and other
Versamune(®) based products and the Company’s interpretation of the results
and findings of such programs and collaborations and whether such results are
sufficient to support the future success of the Company’s product
candidates; the success, timing and cost of the Company’s ongoing clinical
trials and anticipated clinical trials for the Company’s current product
candidates, including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to fully fund
our disclosed clinical trials, which assumes no material changes to our
currently projected expenses), futility analyses, presentations at conferences
and data reported in an abstract, and receipt of interim results, which are
not necessarily indicative of the final results of the Company’s ongoing
clinical trials; any Company statements about its understanding of product
candidates mechanisms of action and interpretation of preclinical and early
clinical results from its clinical development programs and any collaboration
studies; the acceptance by the market of the Company’s product candidates,
if approved; the timing of and the Company’s ability to obtain and maintain
U.S. Food and Drug Administration or other regulatory authority approval of,
or other action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations arising from
or related to COVID-19. The foregoing review of important factors that could
cause actual events to differ from expectations should not be construed as
exhaustive and should be read in conjunction with statements that are included
herein and elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking statements
are made only as of the date of this press release and, except as required by
applicable law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking statements,
whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838 
Email: rich@cg.capital


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.